CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
enzastaurindrug
Likely dose
Enzastaurin 500 mg orally dailyAI-extracted
Key inclusion· 5
  • ✓Confirmed mantle cell lymphoma diagnosis
  • ✓Prior treatment for mantle cell lymphoma required
  • ✓Relapsed disease with no more than 4 prior chemotherapy regimens
  • ✓All prior cancer therapies discontinued except corticosteroids up to 25 mg/day
Key exclusion· 2
  • ✕Unable to swallow tablets
  • ✕Significant cardiac disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00088205
NCT00088205Phase 2Completed
CompareCT.gov

A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma

Eli Lilly and Company·interventional·Posted Jul 23, 2004·Updated Jul 1, 2020

In Brief

A Phase 2 clinical trial evaluating enzastaurin for Mantle-Cell Lymphoma. Completed, enrolled 60 participants across 17 sites in 4 countries.

Detailed Summary

The purposes of this study are to determine the safety of oral enzastaurin and any side effects that might be associated with it and whether enzastaurin can help participants with mantle cell lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle-Cell Lymphoma
CountriesAustralia, France, Germany, Netherlands
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 23, 2004
Enrollment StartMar 1, 2004
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 21.9 years ago

Interventions

enzastaurindrug

500 milligrams (mg), oral, daily, up to six 28-day cycles